Grail LLC has presented data showing that when added to standard screening procedures for breast, cervical, colorectal and lung cancers, its Galleri circulating tumor DNA test led to a sevenfold increase in the number of cancers detected.
Biopharma happenings, including deals and partnerships, and other news in brief: Actor, Aculys, Delix, Evoq, Formycon, Jacobio, Jacoray, Klinge, Megalabs, Sanofi, Viatris.
Clinical updates, including data readouts and publications: Aicuris Anti-infective Cures, Aptose, Aqilion, Johnson & Johnson, Ketabon, Merck, Novartis, Praxis Precision, Remegen, Vor.
Caught between the rock and the hard place of most-favored nation (MFN) pricing and the threat of a hefty biopharma sector tariff, drug companies marketing in the U.S. are exploring their options. Several large firms already have committed millions and billions of dollars in investment in new or expanded U.S.-based manufacturing facilities to avoid tariffs on finished drugs.
RSS
